aTyr Pharma, Inc. Common Stock(ATYR)

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership.

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

Snapshot
$0.44
52-Week Range
$0.40 – $7.29
YTD
-41.51%
IV Rank (30D)
58.61
Straddle Price
$0.88
P/C Vol Ratio
0.40
Market Cap
$0.0B
Fair Value
+50.0% vs price
Confidence: 36% Alpha Score: 1.02

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 0.5% and dividend payments are stable.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)4.53%
Beta vs SPY1.00
Cost of Equity (CAPM)10.03% (VRP-adj)
WACC9.99%
Volatility Risk Premium+126.0pp (IV − HV30), ERP adj +50bps
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)+3.0%
DCF Horizon10 years explicit + fade
Forward Tilt (NTM/TTM)×1.03 (applied to P/E, EV/EBITDA, P/S)
Free Cash Flow (TTM)$-0.1B
Return on Equity (TTM)-120.9%
Book / Price128.4% — banking bias active (P/B is primary)
Gross Margin (TTM)100.0%
FCF Margin (TTM)-31209.5%
Debt / Equity0.00
Quality Score2/6 — normal (10y DCF)
SMA 50$0.69 (Market Anchor value)
SMA 20 / Bollinger Mid$0.50
Bollinger Width / SMA204981.1% (drives anchor stability)
Net Debt$-0.0B
Market Cap$0B
Peers used for multiples: BIIB, MRNA, NBIX (filtered from 8 ETF-co-members; sector bias active)
Blended Fair Value
$0.71
Current Price
$0.44
Deviation
+50.0%
Forward-Return Rank LONG gates ✓
?
Horizon Expected α z Pred Blended z Rank % Active?
21d +3.4% +1.95 +1.93 95.6% ACTIVE
42d +2.5% +1.64 +1.78 92.0%
63d +2.8% +1.39 +1.65 89.7%
Expected α = forward-return point estimate vs SPY (e.g., +7.5% means the predictor expects this stock to outperform SPY by 7.5% over that horizon). For SHORT direction the model uses a different ranking metric (conviction-weighted deviation, not the LGBM prediction); Expected α is shown for reference. flags rows where Expected α disagrees with the FV direction — two independent signals are in conflict; conviction is low even if rank looks extreme.
Forward-Return Rank. A proprietary ensemble of a machine-learning forward-return model and a conviction-weighted fundamental score, ranked cross-sectionally each day across the S&P 500 (and broader universes on the screener). Each stock is scored at three horizons (21/42/63 trading days). "Active" = top/bottom 5% AND all risk filters pass. Backtested mean alpha vs SPY on active picks: 21d LONG +13.4%, 63d +34.9% (S&P 500, walk-forward). Past performance is not indicative of future results.
Value vs momentum conflict ⚠. The "FV direction" (long/short) comes from the fundamentals-based engine — price vs intrinsic value. The "Expected α" comes from a separate machine-learning predictor trained on ~12 features (sector, options-implied move, beta, institutional flow, etc.). Sometimes the two disagree: a stock is overvalued by fundamentals but the predictor expects it to keep outperforming (sector or momentum tailwinds). When all 3 horizons disagree, treat the direction signal as low-conviction — neither model is strongly recommending a position.
MethodImplied PriceWeightDetail
DCF n/a 0%
DDM (Gordon) n/a 0%
Peer P/E n/a 0%
Peer EV/EBITDA n/a 0%
Peer P/B $1.50 18% median 2.5× · 3 peers
Peer P/S $0.01 18% median 5.2× · 3 peers
Market Anchor (SMA50) $0.69 63% stability 67% (BB-width)
Options Expected (B-L 30d) n/a 0%
As of 2026-06-12 · updated 2026-06-12 20:59:55.687000
Info
Industry (SIC)
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836)
Exchange
XNAS
Market Cap
$0.0B

aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).

Price History
Seasonality
MonthAvg ReturnYears of Data
Jan +1.43% 2
Feb +7.58% 2
Mar -11.46% 2
Apr +7.72% 2
May -2.63% 2
Jun -7.03% 3
Jul +8.66% 2
Aug +1.80% 2
Sep -45.03% 2
Oct +52.33% 2
Nov -0.19% 2
Dec -2.03% 2
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators
SMA 20: $0.49
SMA 50: $0.68
SMA 200: $1.08
Current: $0.44
EMA 12: $0.49
EMA 26: $0.55
MACD: -0.0643 | Signal: 0.0055
BEARISH
ADX (14): 25.41
TREND
+DI: 15.42
−DI: 26.75
Momentum Oscillators
RSI (14): 37.38
NEUTRAL
Stoch %K: 16.40
Stoch %D: 15.90
Williams %R: -97.16
Volume & Volatility
BB Upper: $0.55
BB Lower: $0.43
NEUTRAL
OBV: -119,000,776
Vol SMA 20: 3,038,552
Vol ROC: -73.79%
ATR: $0.06
True Range: $0.04
HV 20: 92.8%
HV 30: 239.9%
HV 60: 175.1%

Data Summary
Data Points: 500
Last Updated: 2026-06-12T21:15:12.041000
Date Range: 2024-06-14T00:00:00 – 2026-06-12T00:00:00
AI Analysis

Choose Frenzy-Fast™ for quick analysis or Frenzy-Pro™ for comprehensive analysis.

Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.

News
Earnings History
5 of 5 under expected move
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2025-05-07 Pre-Market 64.24% 1.70% 0.03x Within
2025-08-08 Pre-Market 20.04% 1.15% 0.06x Within
2025-11-06 Pre-Market 27.65% 4.15% 0.15x Within
2026-03-05 Pre-Market 36.05% 7.00% 0.19x Within
2026-05-15 Pre-Market 9.62% 3.38% 0.35x Within
Options Activity
IV Rank (30D)
58.61
IV Rank (7D)
100
Avg IV
425.2%
Straddle (30D)
$0.88
Straddle (7D)
$0.75
P/C Volume
0.40
Spread Scanner GPU

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR25 and BF25 from the live options chain. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Volatility Surface

Enter a ticker to render the implied volatility surface.

IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Beta (1Y vs SPY)
2.13
Correlation (SPY)
18.8%
0.04
Ann. Volatility
140.1%
SPY Volatility
12.3%

High volatility - stock moves more than market

Beta & Alpha Over Time
Institutional Ownership (13F)
Latest filings — 2026-03-31
Diluted shares outstanding: 94,575,743 (as of 2026-03-31)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

108 filers56,181,430 shares$42.45M value59.40% of float
# Filer Shares Value % of Total % of Float Period
1 FMR LLC Custodian 14,706,843 $11.47M 27.02% 15.55% 2026-03-31
2 FEDERATED HERMES, INC. 10,509,678 $8.20M 19.31% 11.11% 2026-03-31
3 BlackRock, Inc. Custodian 6,443,904 $5.03M 11.84% 6.81% 2026-03-31
4 VANGUARD GROUP INC Custodian 4,961,871 $3.89M 9.15% 5.25% 2025-12-31
5 UBS Group AG Custodian 3,867,213 $3.02M 7.11% 4.09% 2026-03-31
6 GEODE CAPITAL MANAGEMENT, LLC Custodian 2,385,485 $1.86M 4.38% 2.52% 2026-03-31
7 STATE STREET CORP 1,754,399 $1.37M 3.22% 1.85% 2026-03-31
8 MILLENNIUM MANAGEMENT LLC Custodian 1,641,246 $1.28M 3.02% 1.74% 2026-03-31
9 MORGAN STANLEY Custodian 1,403,009 $1.10M 2.59% 1.48% 2025-12-31
10 TWO SIGMA INVESTMENTS, LP 1,144,565 $892.76K 2.10% 1.21% 2026-03-31
11 SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian 866,744 $676.06K 1.59% 0.92% 2026-03-31
12 NORTHERN TRUST CORP Custodian 711,105 $554.66K 1.31% 0.75% 2026-03-31
13 AQR CAPITAL MANAGEMENT LLC Custodian 496,018 $386.89K 0.91% 0.52% 2026-03-31
14 BANK OF AMERICA CORP /DE/ Custodian 303,559 $236.78K 0.56% 0.32% 2026-03-31
15 GOLDMAN SACHS GROUP INC Custodian 283,236 $220.92K 0.52% 0.30% 2026-03-31
16 Nuveen, LLC Custodian 229,284 $178.84K 0.42% 0.24% 2026-03-31
17 CHARLES SCHWAB INVESTMENT MANAGEMENT INC 210,737 $164.38K 0.39% 0.22% 2026-03-31
18 Bank of New York Mellon Corp Custodian 193,531 $150.95K 0.36% 0.20% 2026-03-31
19 GROUP ONE TRADING LLC Custodian 184,014 $143.53K 0.34% 0.19% 2026-03-31
20 MARSHALL WACE, LLP Custodian 138,118 $107.73K 0.25% 0.15% 2026-03-31
21 XTX Topco Ltd 111,423 $86.91K 0.20% 0.12% 2026-03-31
22 DEUTSCHE BANK AG\ Custodian 103,326 $80.59K 0.19% 0.11% 2026-03-31
23 RHUMBLINE ADVISERS 103,146 $80.44K 0.19% 0.11% 2026-03-31
24 HOHIMER WEALTH MANAGEMENT, LLC 100,000 $78.00K 0.18% 0.11% 2026-03-31
25 DIMENSIONAL FUND ADVISORS LP Custodian 91,871 $71.48K 0.17% 0.10% 2026-03-31
9 filers$929.42K notional
# Filer Notional Value % of Total Period
1 JANE STREET GROUP, LLC Custodian $353.26K 38.01% 2026-03-31
2 WOLVERINE TRADING, LLC Custodian $163.10K 17.55% 2025-09-30
3 SIMPLEX TRADING, LLC Custodian $121.29K 13.05% 2026-03-31
4 GROUP ONE TRADING LLC Custodian $117.62K 12.66% 2026-03-31
5 CITADEL ADVISORS LLC Custodian $84.40K 9.08% 2026-03-31
6 SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian $80.11K 8.62% 2026-03-31
7 DIADEMA PARTNERS LP $9.52K 1.02% 2026-03-31
8 Persistent Asset Partners Ltd $122 0.01% 2026-03-31
9 HAP TRADING, LLC $6 <0.01% 2025-09-30
8 filers$390.47K notional
# Filer Notional Value % of Total Period
1 SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian $127.06K 32.54% 2026-03-31
2 WOLVERINE TRADING, LLC Custodian $110.45K 28.29% 2025-09-30
3 GROUP ONE TRADING LLC Custodian $66.38K 17.00% 2026-03-31
4 CITADEL ADVISORS LLC Custodian $37.28K 9.55% 2026-03-31
5 SIMPLEX TRADING, LLC Custodian $34.55K 8.85% 2026-03-31
6 DIADEMA PARTNERS LP $9.75K 2.50% 2026-03-31
7 Persistent Asset Partners Ltd $4.99K 1.28% 2026-03-31
8 FNY Investment Advisers, LLC $0 0.00% 2026-03-31
Insider Activity
Latest: 2026-05-28
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-05-28 PAUL SCHIMMEL Director Buy (P) +100,000 $0.50 $49.6K EDGAR
2026-05-13 Jane A Gross Director Grant (A) +50,000 opt EDGAR
2026-05-13 Sara Zaknoen Director Grant (A) +50,000 opt EDGAR
2026-05-13 Svetlana Lucas Director Grant (A) +50,000 opt EDGAR
2026-05-13 PAUL SCHIMMEL Director Grant (A) +50,000 opt EDGAR
2026-05-13 Timothy Coughlin Director Grant (A) +50,000 opt EDGAR
2026-05-13 ERIC BENEVICH Director Grant (A) +50,000 opt EDGAR
2026-02-04 Sanjay Shukla President and CEO Mixed +6,630 $0.98 -$3.7K EDGAR
2026-02-04 Jill Marie Broadfoot Chief Financial Officer Mixed +2,192 $0.98 -$1.5K EDGAR
2026-02-04 NANCY DENYES General Counsel Mixed +1,569 $0.98 -$1.1K EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
Insider Holdings
4 insiders · @ $0.44
Officers, directors, and 10%+ owners ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 PAUL SCHIMMEL Director 1,421,913 $626.2K $49.6K 2 2026-05-28
2 Sanjay Shukla President and CEO 153,553 $67.6K -$3.7K 1 2026-02-04
3 Jill Marie Broadfoot Chief Financial Officer 38,854 $17.1K -$1.5K 1 2026-02-04
4 NANCY DENYES General Counsel 33,124 $14.6K -$1.1K 1 2026-02-04
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
ETF Holders
# ETF Provider Weight $ Exposure ETF AUM As Of
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

P/B Ratio0.8
P/S Ratio247.7
EV/EBITDA-0.5
TTM Revenue$0.0B
TTM Net Income$-0.1B
TTM EPS$-0.73
ROE-120.9%
Debt/Equity0.01